Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
IMI's overall goal is to build a more collaborative ecosystem for pharmaceutical research and development (R&D) in Europe and to speed up the development of more effective and safer medicines for patients.
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. Funding is distributed through peer-reviewed open calls for proposals.
The research funded under IMI addresses the IMI Scientific Research Agenda. For 2014-2020 this focuses on delivering ‘the right prevention and treatment for the right patient at the right time’ through four main research areas:
- target validation and biomarker research (efficacy and safety)
- adoption of innovative clinical trial paradigms
- innovative medicines
- patient-tailored adherence programmes.